Infliximab versus Adalimumab, Which One Is Better for Ulcerative Colitis?

참고문헌 (10)

1. Feagan BG, "Adalimumab therapy is associated with reduced risk of hospitalization in patients with ulcerative colitis", Gastroenterology, 146, pp.110~118 (2014)
2. Targownik LE, "Temporal trends in initiation of therapy with tumor necrosis factor antagonists for patients with inflammatory bowel disease : a population-based analysis", Clin Gastroenterol Hepatol, 15, pp.1061~1070 (2017)
3. Philip W. Jenkinson, "Analysis of colectomy rates for ulcerative colitis in pre‐ and postbiological eras in Lothian, Scotland", Colorectal Disease, 23(5), pp.1175~1183 (2021), Wiley[DOI]
4. LeBlanc K, "The impact of biological interventions for ulcerative colitis on health-related quality of life", Cochrane Database Syst Rev, (9), pp.CD008655~ (2015)
5. Thorlund K, "Adalimumab versus infliximab for the treatment of moderate to severe ulcerative colitis in adult patients naïve to anti-TNF therapy : an indirect treatment comparison metaanalysis", J Crohns Colitis, 8, pp.571~581 (2014)
6. Lee Yong Il, "Comparison of Long-Term Outcomes of Infliximab versus Adalimumab Treatment in Biologic-Naïve Patients with Ulcerative Colitis", Gut and Liver, 15(2), pp.232~242 (2021), 거트앤리버 소화기연관학회협의회[DOI]
7. Singh S, "Comparison of infliximab and adalimumab in biologic-naive patients with ulcerative colitis : a nationwide Danish cohort study", Clin Gastroenterol Hepatol, 15, pp.1218~1225 (2017)
8. Singh S, "Comparative effectiveness and safety of infliximab and adalimumab in patients with ulcerative colitis", Aliment Pharmacol Ther, 43, pp.994~1003 (2016)
9. Pouillon L, "Treatment persistence of infliximab versus adalimumab in ulcerative colitis : a 16-year single-center experience", Inflamm Bowel Dis, 25, pp.945~954 (2019)
10. Chen C, "Real-world pattern of biologic use in patients with inflammatory bowel disease : treatment persistence, switching, and importance of concurrent immunosuppressive therapy", Inflamm Bowel Dis, 25, pp.1417~1427 (2019)